Over 570 healthy adults in the US and Europe were given one of two dose levels of the vaccine in three injections, while others were given a placebo as a control. Both groups that received the active dose were found to have produced a significant amount of antibodies against each of the six most prevalent Outer Surface Protein A serotypes of B. burgdorferi. […] This new potential vaccine, known as VLA15, is currently the only active Lyme disease vaccine in clinical development. Back in 1998, the US Food and Drug Administration (FDA) approved a Lyme disease vaccine known as LYMErix. It was withdrawn from the market just three years later following doubts over its effectiveness and other contentions. Much of the controversy, however, was often said to have been kicked up by the anti-vaccination movement, which was growing in momentum at the time.
Read more of this story at Slashdot.